Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders | terminated | Phase 1 | 4 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 |
| clinicaltrials |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | terminated | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00450814 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 48 | Mayo ClinicOTHER | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02057640 | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Jason ValentOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04194931 | Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01239368 | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01503242 | 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 | 15 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT03720496 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy | unknown | Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00861510 | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | completed | Phase 1 | 16 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02254772 | A Phase I/II Study of Intratumoral Injection of SD-101 | completed | Phase 1 / Phase 2 | 9 | Robert LowskyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02189343 | Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | completed | Phase 1 | 16 | CelgeneINDUSTRY | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Pharmacyclics LLC.INDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02579824 | Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00109109 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) | terminated | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 14, 2019 | clinicaltrials |
| NCT00555100 | Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma | completed | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01568294 | Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01937442 | Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma | completed | Phase 1 | 7 | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT00005792 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | completed | Phase 1 | 131 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01351935 | Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | completed | Phase 1 | 113 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT02289222 | 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 48 | Ashraf BadrosOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04026100 | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 1 | 9 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT00834665 | Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma | completed | Phase 1 | 59 | University of PennsylvaniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01142232 | Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma | completed | Phase 1 / Phase 2 | 60 | Attaya SuvannasankhaOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT01076543 | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02043860 | Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma(BMT-02) | terminated | Phase 1 | 3 | University of Illinois at ChicagoOTHER | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02215967 | Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2019 | clinicaltrials |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis | terminated | Phase 1 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | terminated | Phase 1 | 2 | Michael ChoiOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT03618602 | Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients | unknown | Phase 1 | 30 | Shanghai Theorion Pharmaceutical Co Ltd.INDUSTRY | 1 | Sep 19, 2019 | clinicaltrials |
| NCT03379584 | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma | terminated | Phase 1 | 14 | Seagen Inc.INDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia(8400-401) | terminated | Phase 1 / Phase 2 | 31 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03497533 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19(Trident19-H) | unknown | Phase 1 / Phase 2 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT03657420 | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02954796 | A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 27 | Seagen Inc.INDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT00932698 | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01001442 | Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02950220 | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 | 2 | Kami MaddocksOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01699152 | Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 | 16 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 25, 2019 | clinicaltrials |
| NCT01638936 | BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04025450 | Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2019source: clinicaltrials